Below is the information acquired on DIASORIN S.P.A., which is not yet included in our research perimeter.

To request an evaluation of this company and its inclusion in the OpenCorporation Ranking or if you have additional, different and more updated data than what is published in this OpenCorporation company card, please write to info@opencorporation.org so that our team may take it in account.

Last update 28 May 2020

Description of economic activities

Manufacture of pharmaceutical preparations (NACE2 2120)

This company is primarily engaged in the development and manufacture of basic pharmaceutical products and re-agents for in vitro diagnostics. It was founded by Fiat and Montecatini in 1968. It conducts business from its registered head office located in Saluggia, Italy. The company develops and manufactures a large catalog of diagnostic tests that are designed for hospital and private testing laboratories for use in various clinical areas in the market of immunodiagnostics and molecular diagnostics. It offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; stool diagnostics; autoimmunity; and cardiac and brain damages. Its immunodiagnostics systems include LIAISON XL, an automated chemiluminescence analyzer; LIAISON analyzer; EVOlyzer 2-150/8 with disposable tips; and ETI Max 3000, an automated microtiter plate analyzer. Its mission is to contribute to the improvement of health care by bringing to market diagnostic tests that can orient better medical decisions, while curbing public health care costs. The company sells its products worldwide directly through 11 subsidiaries and branch offices and as well as through an international network of more than 80 distributors. Two additional production sites are located in Stillwater, Minnesota in the United Kingdom, and in Dietzenbach, Germany. The company is also active in the United States, Mexico, Brazil, the United Kingdom, France, Spain, Belgium, Sweden, Germany, Israel, and China.
  • DIASORIN S.P.A.

  • Italy (IT)
  • Company type: Corporate
  • Parent company: IP INVESTIMENTI E PARTECIPAZIONI S.R.L. O BREVEMENTE IP S.R.L.
  • Chief Executive Officer (CEO): Mr Gustavo Denegri
  • CEO Total remuneration: N/A
  • Website: www.diasorin.com

Financial data

Number of employees

1,939
1,971
1,896
1,841

Revenue *

706.319
670.496
637.487
570.663

EBIT *

218.984
206.82
187.046
177.255

EBITDA *

277.956
257.646
238.88
N/A

* numbers are in millions

  • RepRisk Indicator (last month)*: 32

Social dialog

  • Transnational Corporate Agreement (TCA): N/A
  • Global Framework Agreement (GFA): N/A
  • Societas Europaea (SE): N/A
  • Bangladesh Accord: N/A

European Works Councils

  • EWC*: N/A

Standards and certifications

Global Reporting Initiative certification*

  • Global Reporting Initiative standards: N/A
  • Global Reporting Initiative GRI G4: N/A

Other company declarations

  • Corporate Social Responsability:
    N/A
  • Accessibility: N/A

Policies

  • Training policy: N/A
  • Policy to protect the right to health and safety in the workplaces where the company operates: N/A
  • Policy to protect the right to health and safety in the workplaces in the supply chain: N/A
  • Diversity policy: N/A

Universal declarations

Declarations and treaties recognised by the country where the company has its registered office

  • Universal Declaration of Human Rights:
  • European Convention on Human Rights (ECHR):
  • Charter of Fundamental Rights of CDFL Workers (Strasbourg Charter 1989):
  • Charter of Fundamental Rights of the European Union EU CFR (Nice Charter 2000):
  • Treaty on the Functioning of the European Union TFEU:
  • Registered office in an OECD country:
  • ILO C029 - Forced Labour Convention, 1930 (No. 29):
  • ILO C087 - Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87):
  • ILO C098 - Right to Organise and Collective Bargaining Convention, 1949 (No. 98):
  • ILO C100 - Equal Remuneration Convention, 1951 (No. 100):
  • ILO C105 - Abolition of Forced Labour Convention, 1957 (No. 105):
  • ILO C111 - Discrimination (Employment and Occupation) Convention, 1958 (No. 111):
  • ILO C138 - Minimum Age Convention, 1973 (No. 138):
  • ILO C182 - Worst Forms of Child Labour Convention, 1999 (No. 182):

Directives applied in the company offices in EU 27

  • D. 80/987/EEC:
  • D. 89/391/EEC:
  • D. 98/59/EC:
  • D. 2000/43/EC:
  • D. 2000/78/EC:
  • D. 2001/23/EC:
  • Council D. 2001/86/EC:
  • D. 2002/14/EC:
  • D. 2002/73/EC:
  • Council D. 2003/72/EC:
  • EP and Council D. 2005/56/EC:
  • D. 2009/38/EC:
  • D. 2004/25/EC:
  • D. 2011/35/EU:

Presence in main rankings

  • Global 100 Most Sustainable Corporations: N/A
  • Global CSR Rep Trak 100: N/A
  • BrandZ Top 100 Most Valuable US Brands: N/A
  • The Worlds Best Multinational Workplaces: N/A
  • The Gartner Supply Chain Top 25: N/A
  • The Worlds Most Innovative Companies: N/A
  • The Diversity Inc Top 50 Companies: N/A
  • Best Global Websites: N/A
  • Green Ranking Global Top 500: N/A
  • Green Ranking Global Top 100: N/A

Latest news about diasorin s.p.a.

10 March 2020 - 18:00

Diasorin, test rapido per il coronavirus entro fine marzo

Risultati in 60 minuti invece di 5-7 ore, il titolo vola a Piazza Affari

DiaSorin ha completato presso l'ospedale Spallanzani di Roma e il Policlinico San Matteo di Pavia, gli studi necessari per supportare l'approvazione di un innovativo test molecolare per l'identificazione rapida del nuovo coronavirus Covid-19.

› source:  La Stampa
10 March 2020 - 10:00

Coronavirus, test rapido Diasorin entro fine marzo per identificare il virus in 60 minuti

Diasorin annuncia di aver completato presso l'Ospedale Spallanzani di Roma ed il Policlinico San Matteo di Pavia, gli studi necessari per supportare l'approvazione Ce e Fda di un innovativo test molecolare per l'identificazione rapida del nuovo coronavirus Covid-19. Il test è sviluppato per essere eseguito sull'analizzatore Liaison* Mdx e consente di ottenere risultati entro 60 minuti, rispetto alle 5-7 ore attualmente necessarie con altre metodologie.

› source:  Il Messaggero